CN1092812A - 疫苗 - Google Patents

疫苗 Download PDF

Info

Publication number
CN1092812A
CN1092812A CN93109561A CN93109561A CN1092812A CN 1092812 A CN1092812 A CN 1092812A CN 93109561 A CN93109561 A CN 93109561A CN 93109561 A CN93109561 A CN 93109561A CN 1092812 A CN1092812 A CN 1092812A
Authority
CN
China
Prior art keywords
protein
hsv
sequence
dna
icp27
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN93109561A
Other languages
English (en)
Chinese (zh)
Inventor
M·施劳伊
P·帕拉
M·库祖科斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of CN1092812A publication Critical patent/CN1092812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN93109561A 1992-06-25 1993-06-24 疫苗 Pending CN1092812A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9213559A GB9213559D0 (en) 1992-06-25 1992-06-25 Vaccines
GB9213559.9 1992-06-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN97110399A Division CN1222393A (zh) 1992-06-25 1997-04-19 疫苗组合物及其制备方法

Publications (1)

Publication Number Publication Date
CN1092812A true CN1092812A (zh) 1994-09-28

Family

ID=10717757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93109561A Pending CN1092812A (zh) 1992-06-25 1993-06-24 疫苗

Country Status (11)

Country Link
EP (1) EP0649470A1 (enrdf_load_stackoverflow)
JP (1) JPH07508648A (enrdf_load_stackoverflow)
KR (1) KR950702244A (enrdf_load_stackoverflow)
CN (1) CN1092812A (enrdf_load_stackoverflow)
AU (2) AU676166B2 (enrdf_load_stackoverflow)
CA (1) CA2138996A1 (enrdf_load_stackoverflow)
GB (1) GB9213559D0 (enrdf_load_stackoverflow)
MX (1) MX9303771A (enrdf_load_stackoverflow)
NZ (1) NZ253138A (enrdf_load_stackoverflow)
TW (1) TW269635B (enrdf_load_stackoverflow)
WO (1) WO1994000575A1 (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100633212B1 (ko) * 1998-02-05 2006-10-11 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신접종을 위한 융합 단백질 및 조성물의 제조를 위해사용되는 ｍａｇｅ 군으로부터의 종양 관련 항원 유도체및 이들을 암호화하고 있는 핵산 서열
DK1092779T3 (da) * 1999-10-11 2010-02-15 Pasteur Institut Lentiviirusvektorer til fremstilling af immunterapeutiske præparater
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection

Also Published As

Publication number Publication date
CA2138996A1 (en) 1994-01-06
EP0649470A1 (en) 1995-04-26
WO1994000575A1 (en) 1994-01-06
TW269635B (enrdf_load_stackoverflow) 1996-02-01
MX9303771A (es) 1994-05-31
JPH07508648A (ja) 1995-09-28
KR950702244A (ko) 1995-06-19
NZ253138A (en) 1995-10-26
GB9213559D0 (en) 1992-08-12
AU1785597A (en) 1997-06-19
AU676166B2 (en) 1997-03-06
AU4326493A (en) 1994-01-24

Similar Documents

Publication Publication Date Title
Zhao et al. Preliminary study of an oral vaccine against infectious hematopoietic necrosis virus using improved yeast surface display technology
JP5300479B2 (ja) 魚類ワクチン
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
JPH06506705A (ja) 再発性ｈｓｖ感染用の免疫療法
EP2391383B1 (en) Codon-optimized hepatitis b virus core antigen (hbcag)
Li et al. Development of a live vector vaccine against infectious hematopoietic necrosis virus in rainbow trout
He et al. Protection of goldfish against Ichthyophthirius multifiliis by immunization with a recombinant vaccine
CN112500458A (zh) 鸡传染性法氏囊病病毒新型变异株亚单位疫苗、其制备方法及应用
KR20150036057A (ko) 재조합체 ｂｔｖ 및 ａｈｓｖ 백신
WO1995016779A9 (en) Herpes-symplex-virus type 2 icp4 protein and its use in a vaccine composition
CN112159480A (zh) 一种鸡传染性法氏囊病病毒多抗原表位蛋白及其应用
Aravind et al. Protective effects of recombinant glycoprotein D based prime boost approach against duck enteritis virus in mice model
CN103352047B (zh) 旋毛虫肌幼虫es抗原基因疫苗及其制备方法
WO2013102492A1 (en) Synthetic genes encoding peptide fragments of natural myelin proteins for induction of oral tolerance, dna fragment comprising these genes, means of obtaining these peptides in a microbial (bacterial) system and their medical application
CN1092812A (zh) 疫苗
JP2780961B2 (ja) 単純ヘルペスウイルスタンパク質およびそれを含む ワクチン
CN1047531A (zh) 猪瘟病毒疫苗和诊断
CN103589693A (zh) 一种表达ibdv vp2和法氏囊素三肽嵌合蛋白重组火鸡疱疹病毒
CN106967174A (zh) 多肽融合蛋白gwp在抗立氏立克次体的免疫保护中的应用
JP2000502900A (ja) 組換えウイルス偽粒子ならびにそのワクチンおよび抗腫瘍性用途
CN101768575B (zh) 双表达g基因的重组狂犬病病毒的构建及其生物学特性分析
CN1053642A (zh) 传染性支气管炎病毒疫苗
CN1035126A (zh) 编码狂犬病毒糖蛋白的基因片段及用此片段制备狂犬病毒糖蛋白的方法
CN1222393A (zh) 疫苗组合物及其制备方法
JPH03503237A (ja) 細胞性応答を誘発するトリコクシジウム症抗原をコードするクローン化遺伝子、およびその製造方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C01 Deemed withdrawal of patent application (patent law 1993)
WD01 Invention patent application deemed withdrawn after publication